Intense pulsed light (IPL) and broadband light (BBL) are the workhorses of the "photofacial" — a light treatment that fades sun spots, redness, and broken vessels with little to no downtime. Done well, on the right patient, with the right settings, they are effective and routine. Done on the wrong skin type, on tanned skin, or by an undertrained operator, the same devices produce burns, blistering, and pigment changes that can take months to fade — or, in the case of lightening (hypopigmentation), may not fade at all.
Two things are worth knowing up front. First, the pigment risk is not symmetric across skin types. IPL and BBL target melanin, which is exactly why they clear sun spots — and exactly why they burn darker skin. The published side-effect rates climb sharply from Fitzpatrick type I to type VI. Second, U.S. public adverse-event reports for light-based devices have spiked since 2023, and the single biggest driver is not a clinic laser — it is at-home light devices. That is a new pattern in the data, and it changes who is getting hurt.
This article walks through what the public FDA device-event database shows for IPL, BBL, and at-home light devices; what the clinical literature reports for burn and pigment rates by skin type; and what to ask a provider before booking. It is educational and is not a substitute for an individualized consultation with a qualified clinician.
How IPL and BBL work — and why they burn
Both IPL and BBL deliver a broad band of light (not the single wavelength of a true laser) in pulses. The light is absorbed by two chromophores in the skin: melanin (pigment) and hemoglobin (in blood vessels). Absorbed energy becomes heat. For a sun spot, that heat damages the pigmented cell so the spot darkens, crusts, and flakes off over days. For a visible vessel, heat injures the vessel wall so it collapses.
The therapeutic window — the margin between enough heat to treat the target and so much heat that the surrounding skin is injured — is narrow. Melanin sits in the epidermis, the skin's top layer, regardless of where the target is. If the skin itself is dark, tanned, or recently inflamed, the surface melanin absorbs energy that was meant for a deeper target, the epidermis overheats, and the result is a burn. The same mechanism that clears a sun spot creates a new one: thermal injury to melanocytes triggers post-inflammatory hyperpigmentation (PIH), a darkening that can persist for months. Enough injury, or injury in already-light skin, can instead destroy pigment cells and leave permanent light spots (hypopigmentation).
What public device-event reports show
The FDA's Manufacturer and User Facility Device Experience (MAUDE) database collects adverse-event reports for medical devices, including aesthetic light devices. An analysis of public MAUDE records for the three FDA product codes covering professional IPL and consumer light-based skin devices (extract dated 2026-06-10) found the breakdown below.
The professional IPL/BBL code (ONF — broad-spectrum IPL) holds a relatively small number of reports, reflecting a mature, clinic-based technology. The combined picture across professional and over-the-counter (OTC) light devices is more revealing:
| Product code | Device category | Reports |
|---|---|---|
| ONF | Professional IPL / broad-spectrum (BBL) | 34 |
| OHS | OTC light-based wrinkle-reduction devices | 86 |
| OHT | OTC light-based hair-removal devices | 31 |
| Combined light-based, non-laser devices | 154 |
By event type, the combined 154 reports break down as 128 injuries, 21 malfunctions, one death, and two other/unknown. The professional IPL/BBL reports name familiar clinic platforms — Lumecca, the iLight family, BBL paired with Halo, and Sciton systems.
The at-home device spike
The clearest signal in the data is temporal. Combined light-device reports hovered in the single digits per year through 2022, then climbed: 14 in 2023, and 48 in 2025, with 37 already logged in the partial 2026 extract. The increase is driven almost entirely by over-the-counter devices, and one product dominates.
SharkNinja's Shark CryoGlow, an at-home LED face mask cleared by the FDA (510(k) K242796) as an OTC wrinkle-reduction device, accounts for roughly a third of the combined reports — 53 events, concentrated in 2025–2026. A second cluster involves OTC at-home IPL and laser hair-removal devices (product code OHT), including at least one report listing a fatal outcome and "required intervention."
Two cautions on reading this. MAUDE is a passive reporting system: a spike can reflect rising sales and awareness as much as rising harm, and reporting volume is not an incidence rate. And an OTC LED mask causing a skin reaction is a different event from a clinic BBL burn. But the data does make one point that clinicians and the FDA have been making separately: energy-based skin devices are now widely used at home, by lay users, without a patch test or a skin-type assessment, and a measurable share of them produce injuries. The FDA has stated plainly, in a related context, that RF microneedling "is a medical procedure, not a cosmetic treatment, and these devices should not be used at home" — a principle that extends to any device delivering enough energy to injure skin.
What the clinical literature reports for burns and pigment
Device-event databases capture the severe tip of the iceberg. The day-to-day side-effect rate of IPL comes from clinical studies.
In a randomized trial of IPL in 15 subjects (Fitzpatrick types II–IV), Thaysen-Petersen and colleagues recorded the following reactions — a useful illustration of how common even "expected" side effects are:
| Reaction | Rate |
|---|---|
| Erythema (redness) | 87% |
| Hyperpigmentation | 60% |
| Purpura (bruising) | 27% |
| Blisters | 20% |
| Hypopigmentation | 20% |
| Edema (swelling) | 13% |
| Crusting | 13% |
That study also found that darker baseline pigmentation and higher IPL fluence (energy) were both significantly correlated with more severe side effects. This is the core problem in skin of color: the same melanin the device is designed to target is present in higher concentration across the whole treatment area, so the margin for error shrinks. Published reviews put IPL-induced hyperpigmentation at roughly 16% in general use and as high as 45% in patients with Fitzpatrick types IV–VI. A 2025 case report documented second-degree facial burns with PIH in a Fitzpatrick type IV patient treated at a non-medical aesthetic spa where his pain during the session was dismissed.
The practical consequence is a skin-type ceiling on who should be treated. IPL and BBL are generally well suited to Fitzpatrick I–III, can be used cautiously in type IV with conservative settings and a patch test, and carry high PIH and burn risk in types V–VI, where they are typically avoided in favor of longer-wavelength, less melanin-absorbed options such as the 1064 nm Nd:YAG laser.
The contraindications that actually cause burns
Most IPL and BBL injuries trace back to a patient who should not have been treated that day, or at all. The recurring contraindications are:
- A tan — natural or from self-tanner. Tanned skin is primed to absorb light energy. Clinics generally require no sun exposure or tanning for two to four weeks before treatment and discontinuation of self-tanners for around four weeks.
- Isotretinoin (Accutane) within roughly six months. Isotretinoin impairs wound healing and thins the skin; it is a near-universal hold.
- Photosensitizing medications and supplements. Doxycycline, minocycline, St. John's Wort, and certain other drugs lower the burn threshold. A responsible clinic asks for the full medication list and, if needed, stops the agent (with the prescribing clinician's okay) and patch-tests before treating.
- Active tan is the most common avoidable cause of a burn; a missed photosensitizing medication is the most common cause of an unexpected one.
- Pregnancy and breastfeeding — IPL is generally avoided.
- Active skin infection, open lesions, or a cold-sore outbreak in the area — light can be delivered, but treatment is usually deferred; a history of cold sores warrants antiviral prophylaxis.
- Keloid or raised-scarring history.
- Fitzpatrick V–VI without a provider specifically experienced in darker skin — a relative, not absolute, contraindication, but a real one.
The patch test and how to compare clinic protocols
If you are Fitzpatrick IV or higher, on any new medication, or simply cautious, a patch test is the single most useful pre-treatment step: the provider delivers one or a few pulses at the planned settings on a small, inconspicuous area and waits to see how the skin responds. U.K. laser and IPL safety guidance recommends waiting roughly four to seven days after a patch test before hair-removal treatment, and four to six weeks before vascular or pigmented-lesion treatment, because pigment changes can take weeks to declare themselves.
When comparing clinics, the protocol questions that separate a careful operator from a careless one are concrete:
- What Fitzpatrick type am I, and how does that change your settings? A provider who can name your type and explain lower-fluence, longer-pulse adjustments for darker skin is reading from the clinical playbook. One who applies the same settings to everyone is not.
- Do you patch-test, and how long do you wait before the full treatment? A patch test with an adequate wait is standard for higher-risk skin; a same-day full-face treatment on darker skin is a red flag.
- What is your sun-exposure and self-tanner rule before treatment? Anything shorter than two weeks, or no rule at all, is a problem.
- Which medications and supplements stop me from being treated, and for how long? A specific list (isotretinoin, doxycycline, minocycline, St. John's Wort) shows the clinic screens for photosensitizers.
- What device are you using, and is it appropriate for my skin? IPL and BBL are platforms; for Fitzpatrick V–VI, a 1064 nm Nd:YAG is generally safer.
- What is the plan if I burn or develop pigment change? A clinic that mentions PIH, topical lighteners, strict sun protection, and a follow-up interval has a real aftercare plan.
If a burn or pigment change develops
For a reaction that appears during or right after treatment:
- Tell the operator immediately if the pain is more than a brief rubber-band snap. Sharp, escalating, or "different" pain is the earliest sign that the energy is too high for your skin; the case report cited above describes a patient whose pain during a session was dismissed and who went on to second-degree burns.
- Cool the skin gently — a cool, damp compress, not ice directly on the skin — and avoid anything that traps heat. Blistering warrants same-day contact with the clinic.
- Don't pick at crusting or peeling skin. Picking converts a superficial injury into a scar or a permanent pigment mark.
- Strict sun protection from day one — mineral SPF 30 or higher, re-applied through the day, plus hats and shade. Sun exposure during healing is the single biggest driver of post-inflammatory hyperpigmentation after a burn.
For established pigment change, the two directions differ. Hyperpigmentation (darkening) usually fades over weeks to months with sun avoidance and, when a clinician recommends it, topical lighteners; hypopigmentation (lightening) is harder to treat, can be permanent, and may need specialist repigmentation work. If light spots appear, ask a dermatologist early — the options narrow the longer pigment cells are gone.
Limitations
MAUDE is a passive, voluntary system: it captures a fraction of adverse events, is biased toward severe or unusual reports, and a report's presence does not prove the device caused the outcome. The at-home device spike reflects both rising consumer use and reporting behavior, not a clean incidence rate. The clinical side-effect rates cited (Thaysen-Petersen; the 16% and 45% figures) come from specific study populations and protocols and will vary with device, settings, operator, and skin type. Nothing here is a substitute for an in-person assessment by a qualified provider who can see and test your skin.
Sources
- U.S. FDA, MAUDE (Manufacturer and User Facility Device Experience) database — analysis of adverse-event reports for professional IPL (product code ONF), OTC light-based wrinkle-reduction (OHS), and OTC light-based hair-removal (OHT) devices, extract dated 2026-06-10: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/
- MAUDE adverse-event report, SharkNinja Shark CryoGlow (OTC light-based wrinkle reduction, 510(k) K242796): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=22160931
- U.S. FDA, "Potential Risks with Certain Uses of Radiofrequency Microneedling" — safety communication (principle that energy-based aesthetic devices are medical procedures, not home cosmetic treatments): https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
- Thaysen-Petersen L et al., IPL side-effect data, as cited in Kim J, Cartier M, Morcos M. "Second-Degree Burns Following Intense Pulsed Light Therapy in a Patient With Fitzpatrick Skin Type IV: A Case Report." Cureus 2025;17(8):e90119 (erythema 87%, hyperpigmentation 60%, blisters 20%, hypopigmentation 20%; fluence and skin type correlate with severity): https://www.cureus.com/articles/393474-second-degree-burns-following-intense-pulsed-light-therapy-in-a-patient-with-fitzpatrick-skin-type-iv-a-case-report.pdf
- Cosmetic Considerations in Dark-Skinned Patients — PMC (IPL hyperpigmentation up to 45% in Fitzpatrick IV–VI; Nd:YAG 1064 nm safer for darker skin; lower fluence and cooling in skin of color): https://pmc.ncbi.nlm.nih.gov/articles/PMC10844008
- Low-Energy Intense Pulsed Light for Hair Removal at Home — PMC (at-home IPL device trial; face use prohibited; adverse events including burn, pigment change, scarring): https://pmc.ncbi.nlm.nih.gov/articles/PMC2921762
- Successful Re-Pigmentation of IPL-Induced Hypopigmentation — PMC (topical bimatoprost for laser- and IPL-induced hypopigmentation; hypopigmentation is difficult to treat and may be permanent): https://pmc.ncbi.nlm.nih.gov/articles/PMC12729481
- BMLA (British Medical Laser Association), "Drugs and Lasers/IPLs" (photosensitizing medications; isotretinoin; patch-test intervals): https://bmla.co.uk/drugs-and-laser-ipls
